Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 23, 2005. The report details corporate actions regarding share buybacks and updates on directors' interests in company shares held through employee benefit trusts and retirement plans.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes and share ownership data.
- Treasury Shares Held: 92,033,000 (as of May 23, 2005).
- Shares in Issue (excluding treasury): 5,850,465,354 (as of May 23, 2005).
- Share Buyback Price (May 20): 1,348.27 pence per share.
- Share Buyback Price (May 23): 1,346.3373 pence per share.
- US ADR Fund Average Price: $49.95.
Material Changes
The primary material changes involve the reduction of outstanding shares through treasury purchases and minor adjustments in directors' beneficial interests via employee plans.
- Share Repurchases: The Company purchased 750,000 shares on May 20, 2005, and 500,000 shares on May 23, 2005, totaling 1.25 million shares.
- Treasury Increase: Treasury holdings increased from 91,533,000 to 92,033,000 shares following the May 23 transaction.
- US ADR Movement: The GlaxoSmithKline US Retirement Savings Plan saw a decrease in Ordinary Share ADRs from 18,264,444 to 18,243,806 due to fund movements.
- Employee Plan Transactions: Various transfers and sales occurred within the SmithKline Beecham Employee Benefit Trust and the Annual Investment Plan, involving a total of 1,290 shares sold and 1,011 shares transferred to participants.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, management commentary on operations, or discussion of risks and contingencies. It is a procedural disclosure of share transactions and director interests.
Investor Verification Checklist
- Verify the total number of shares authorized for repurchase under the May 2004 Annual General Meeting resolution to assess remaining buyback capacity.
- Confirm the impact of the 1.25 million share reduction on earnings per share (EPS) in upcoming financial reports.
- Review the full composition of the SmithKline Beecham Employee Benefit Trust and US Retirement Savings Plan to understand the extent of director beneficial ownership.
- Check subsequent filings for any further treasury share purchases or cancellations.